Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases

Frontiers in Immunology

Volumn 10, Issue , 2019, Pages

  Taleb, Soraya ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

3 dioxygenase; cardiovascular disease and cardiometabolic diseases; gut microbiota; indoleamine 2; metabolic syndrome; tryptophan

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INCRETIN; INDICAN; INDOLEACETIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 22; KYNURENINE; LIPOPOLYSACCHARIDE; MUCIN; TRYPTAMINE; TRYPTOPHAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;

BIOTRANSFORMATION; CARDIOMETABOLIC RISK; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DEFENSE MECHANISM; DIET SUPPLEMENTATION; DIETARY IMPACTS; ENERGY EXPENDITURE; ENZYME ACTIVITY; FATTY LIVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GUT BARRIER; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; METABOLIC DISORDER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR CROSS-TALK; REVIEW; SYSTEMIC CIRCULATION; TIGHT JUNCTION; TRYPTOPHAN METABOLISM; UPREGULATION; ANIMAL; DIET; INTESTINE; INTESTINE MUCOSA; METABOLISM; MICROFLORA; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIET; GASTROINTESTINAL MICROBIOME; HOST MICROBIAL INTERACTIONS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTESTINAL MUCOSA; INTESTINES; METABOLIC DISEASES; MICE; MICROBIOTA; TRYPTOPHAN;

EID: 85072599649     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.02113     Document Type: Review

References (56)

1. Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metabol. (2017) 26:292–300. 10.1016/j.cmet.2017.07.00828768170
2. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. (2017) 70:1429–37. 10.1016/j.jacc.2017.07.76328911506
3. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. (2008) 57:1470–81. 10.2337/db07-140318305141
4. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. (2018) 359:1376–83. 10.1126/science.aar331829519916
5. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol. (2012) 590:1035–44. 10.1113/jphysiol.2011.22456822219336
6. Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. (2017) 120:1183–96. 10.1161/CIRCRESAHA.117.30971528360349
7. Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. (2016) 22:1079–89. 10.1038/nm.418527711063
8. Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. (2018) 16:171–81. 10.1038/nrmicro.2017.14929307889
9. Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. (2012) 487:477–81. 10.1038/nature1122822837003
10. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. (2013) 39:372–85. 10.1016/j.immuni.2013.08.00323973224
11. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. (2018) 8:13. 10.3389/fcimb.2018.0001329468141
12. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem. (1996) 271:17247–52. 10.1074/jbc.271.29.172478663541
13. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. (2004) 4:762–74. 10.1038/nri145715459668
14. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. (2016) 37:193–207. 10.1016/j.it.2016.01.00226839260
15. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. (2010) 16:279–85. 10.1038/nm.209220190767
16. Metghalchi S, Vandestienne M, Haddad Y, Esposito B, Dairou J, Tedgui A. Indoleamine 2,3-dioxygenase knockout limits angiotensin II-induced aneurysm in low density lipoprotein receptor-deficient mice fed with high fat diet. PLoS ONE. (2018) 13:e0193737. 10.1371/journal.pone.019373729494675
17. Wang Q, Ding Y, Song P, Zhu H, Okon I, Ding YN. Tryptophan-derived 3-hydroxyanthranilic acid contributes to angiotensin ii-induced abdominal aortic aneurysm formation in mice in vivo. Circulation. (2017) 136:2271–83. 10.1161/CIRCULATIONAHA.117.03097228978552
18. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. (2009) 9:445–52. 10.1038/nrc263919461669
19. Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. (2009) 284:19189–95. 10.1074/jbc.M109.02404219473985
20. Iyer SS, Gensollen T, Gandhi A, Oh SF, Neves JF, Collin F. Dietary and microbial oxazoles induce intestinal inflammation by modulating aryl hydrocarbon receptor responses. Cell. (2018) 173:1123–34 e11. 10.1016/j.cell.2018.04.03729775592
21. Romani L, Zelante T, De Luca A, Fallarino F, Puccetti P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol. (2008) 180:5157–62. 10.4049/jimmunol.180.8.515718390695
22. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. (2016) 22:598–605. 10.1038/nm.410227158904
23. Schwarcz R, Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett. (1983) 38:85–90. 10.1016/0304-3940(83)90115-56225037
24. Brandacher G, Winkler C, Aigner F, Schwelberger H, Schroecksnadel K, Margreiter R. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obesity Surg. (2006) 16:541–8. 10.1381/09608920677694506616687019
25. Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, Taront S. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Physiol Regul Integr Comp Physiol. (2012) 303:R135–43. 10.1152/ajpregu.00373.201122592557
26. Mangge H, Stelzer I, Reininghaus EZ, Weghuber D, Postolache TT, Fuchs D. Disturbed tryptophan metabolism in cardiovascular disease. Curr Med Chem. (2014) 21:1931–7. 10.2174/092986732166614030410552624606499
27. Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity. (2015) 23:2066–74. 10.1002/oby.2119926347385
28. Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. (2018) 24:1113–20. 10.1038/s41591-018-0060-429942089
29. Agudelo LZ, Ferreira DMS, Cervenka I, Bryzgalova G, Dadvar S, Jannig PR. Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation. Cell Metabol. (2018) 27:378–92 e5. 10.1016/j.cmet.2018.01.00429414686
30. Anquetil F, Mondanelli G, Gonzalez N, Rodriguez Calvo T, Zapardiel Gonzalo J, Krogvold L. Loss of IDO1 expression from human pancreatic beta-cells precedes their destruction during the development of type 1 diabetes. Diabetes. (2018) 67:1858–66. 10.2337/db17-128129945890
31. Nakajima K, Yamashita T, Kita T, Takeda M, Sasaki N, Kasahara K. Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. (2011) 31:1963–72. 10.1161/ATVBAHA.111.22944321817104
32. Polyzos KA, Ovchinnikova O, Berg M, Baumgartner R, Agardh H, Pirault J. Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe–/– mice. Cardiovasc Res. (2015) 106:295–302. 10.1093/cvr/cvv100
33. Zhang L, Ovchinnikova O, Jonsson A, Lundberg AM, Berg M, Hansson GK. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J. (2012) 33:2025–34. 10.1093/eurheartj/ehs17522711758
34. Cole JE, Astola N, Cribbs AP, Goddard ME, Park I, Green P. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc Natl Acad Sci USA. (2015) 112:13033–8. 10.1073/pnas.151782011226438837
35. Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M. Indoleamine 2,3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metabol. (2015) 22:460–71. 10.1016/j.cmet.2015.07.00426235422
36. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF. Protective role of interleukin-10 in atherosclerosis. Circ Res. (1999) 85:e17–24. 10.1161/01.RES.85.8.e1710521249
37. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. (2014) 511:184–90. 10.1038/nature1332324930766
38. Gutierrez-Vazquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. (2018) 48:19–33. 10.1016/j.immuni.2017.12.01229343438
39. Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the cardiovascular risk in young finns study. Clin Exp Immunol. (2007) 148:106–11. 10.1111/j.1365-2249.2007.03325.x17349013
40. Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the health 2000 study. Scand J Clin Lab Invest. (2008) 68:767–70. 10.1080/0036551080224568518622801
41. Pedersen ER, Midttun O, Ueland PM, Schartum-Hansen H, Seifert R, Igland J. Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. (2011) 31:698–704. 10.1161/ATVBAHA.110.21932921183733
42. Eussen SJ, Ueland PM, Vollset SE, Nygard O, Midttun O, Sulo G. Kynurenines as predictors of acute coronary events in the hordaland health study. Int J Cardiol. (2015) 189:18–24. 10.1016/j.ijcard.2015.03.41325885868
43. Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF. Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol. (2015) 35:455–62. 10.1161/ATVBAHA.114.30467425524770
44. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA. (2009) 106:3698–703. 10.1073/pnas.081287410619234110
45. Martin-Gallausiaux C, Larraufie P, Jarry A, Beguet-Crespel F, Marinelli L, Ledue F. Butyrate produced by commensal bacteria down-regulates indolamine 2,3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. (2018) 9:2838. 10.3389/fimmu.2018.0283830619249
46. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F. The microbiome–gut–brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. (2013) 18:666–73. 10.1038/mp.2012.7722688187
47. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metabol. (2018) 28:737–49 e4. 10.1016/j.cmet.2018.07.00130057068
48. Zelante T, Iannitti RG, Fallarino F, Gargaro M, De Luca A, Moretti S. Tryptophan feeding of the IDO1–AhR axis in host–microbial symbiosis. Front Immunol. (2014) 5:640. 10.3389/fimmu.2014.0064025566253
49. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. (2014) 514:237–41. 10.1038/nature1356425119041
50. Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V. An interleukin-23–interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity. (2018) 49:943–57 e9. 10.1016/j.immuni.2018.09.01130389414
51. Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. (2014) 41:296–310. 10.1016/j.immuni.2014.06.01425065623
52. Crane JD, Palanivel R, Mottillo EP, Bujak AL, Wang H, Ford RJ. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med. (2015) 21:166–72. 10.1038/nm.376625485911
53. Konopelski P, Ufnal M. Indoles—Gut bacteria metabolites of tryptophan with pharmacotherapeutic potential. Curr Drug Metabol. (2018) 19:883–90 10.2174/138920021966618042716473129708069
54. Wlodarska M, Luo C, Kolde R, d'Hennezel E, Annand JW, Heim CE. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe. (2017) 22:25–37.e6. 10.1016/j.chom.2017.06.00728704649
55. Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. (2014) 9:1202–8. 10.1016/j.celrep.2014.10.03225456122
56. Beaumont M, Neyrinck AM, Olivares M, Rodriguez J, de Rocca Serra A, Roumain M. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J. (2018) 32:fj201800544. 10.1096/fj.201800544